Objective: To evaluate the effect of ocrelizumab vs interferon beta-1a (IFNβ-1a) on achieving
no evidence of disease activity (NEDA) in patients with relapsing MS over 96 weeks in two …

Objective To evaluate the efficacy of ocrelizumab compared with interferon beta-1a (IFNβ-
1a) through pooled analysis of efficacy in OPERA I and OPERA II. Background MS …

Background No evidence of disease activity (NEDA; defined as no 12-week confirmed
disability progression, no protocol-defined relapses, no new/enlarging T2 lesions and no T1 …

Objective: To assess the proportion of patients with early relapsing multiple sclerosis (RMS)
with no evidence of disease activity (NEDA) following treatment with ocrelizumab vs …

Objective: To assess the efficacy of switching to or maintaining ocrelizumab (OCR) therapy
on clinical measures of disease activity and progression in the open-label extension (OLE) …

Background The aim of the prospective, multicentre, single-arm Phase IIIb CASTING study
(NCT02861014) is to assess the efficacy/safety of ocrelizumab in patients with relapsing …

Background and purpose Using the treatment goal of “no evidence of disease
activity”(NEDA) incorporating magnetic resonance imaging (MRI) re‐baselining, we aimed …

BACKGROUND: A Phase II RRMS trial showed that ocrelizumab (OCR) reduced Gd+
lesions by> 89% and annualized relapse rate (ARR) by> 73% vs placebo at Week 24. Week …

Objective To assess over 3 years of follow-up the effects of maintaining or switching to
ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open …

Objective: To report year-1 interim analysis results of the single-arm, phase 3b
CONSONANCE study (NCT03523858) designed to evaluate effectiveness and safety of …